Vigil Neuroscience, Inc. (VIGL)

NASDAQ: VIGL · IEX Real-Time Price · USD
2.910
-0.120 (-3.96%)
Apr 17, 2024, 3:07 PM EDT - Market open
-3.96%
Market Cap 107.70M
Revenue (ttm) n/a
Net Income (ttm) -82.64M
Shares Out 36.88M
EPS (ttm) -2.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,826
Open 3.060
Previous Close 3.030
Day's Range 2.820 - 3.130
52-Week Range 2.530 - 11.110
Beta 1.78
Analysts Buy
Price Target 18.50 (+535.74%)
Earnings Date May 8, 2024

About VIGL

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 7, 2022
Employees 69
Stock Exchange NASDAQ
Ticker Symbol VIGL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for VIGL stock is "Buy." The 12-month stock price forecast is $18.5, which is an increase of 535.74% from the latest price.

Price Target
$18.5
(535.74% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP –

22 days ago - GlobeNewsWire

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

4 weeks ago - GlobeNewsWire

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

5 weeks ago - GlobeNewsWire

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

5 weeks ago - GlobeNewsWire

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its differentiated neuroprotective profile and ability to favo...

5 weeks ago - GlobeNewsWire

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

Poster highlights clinical overlap of ALSP and multiple sclerosis (MS)  and details patients' barriers to genetic testing

6 weeks ago - GlobeNewsWire

Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference

WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

2 months ago - GlobeNewsWire

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 -

3 months ago - GlobeNewsWire

Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...

5 months ago - GlobeNewsWire

Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

- Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target engagement and downstream pharmacological activity at 20 mg/kg consistent wit...

5 months ago - GlobeNewsWire

Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update

– Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in ALSP on track for this quarter – – First participant dosed in Phase 1 study of VG-3927, the first and only small molec...

5 months ago - GlobeNewsWire

Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer's Disease

WATERTOWN, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc.  (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

6 months ago - GlobeNewsWire

Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

WATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...

6 months ago - GlobeNewsWire

Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP

WATERTOWN, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

7 months ago - GlobeNewsWire

Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting

- Complete Phase 1 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg -

7 months ago - GlobeNewsWire

Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program

- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer's Disease - - IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed to...

7 months ago - GlobeNewsWire

Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference

WATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

7 months ago - GlobeNewsWire

Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update

- Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in people living with ALSP expected in fourth quarter of 2023 -

9 months ago - GlobeNewsWire

Vigil Neuroscience Appoints Christopher J. Silber, M.D.

WATERTOWN, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...

9 months ago - GlobeNewsWire

Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...

11 months ago - GlobeNewsWire

Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update

- Partial clinical hold lifted by FDA on VGL101 - - Launched ALSPAware to provide access to no-cost genetic testing and counseling for ALSP - - Appointed distinguished biopharmaceutical industry leade...

1 year ago - GlobeNewsWire

Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)

– New genetic testing initiative designed to enable improved patient diagnosis of ALSP, a devastating, rare genetic neurodegenerative disease –

1 year ago - GlobeNewsWire

Vigil Neuroscience to Present at Stifel 2023 CNS Days

WATERTOWN, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

1 year ago - GlobeNewsWire

Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

– Dosed first patient in IGNITE Phase 2 clinical trial to evaluate VGL101 in patients with ALSP –

1 year ago - GlobeNewsWire

Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting

WATERTOWN, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...

1 year ago - GlobeNewsWire